S 4152
A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Bill overview
This bill aims to keep a program called the Critical Path Public-Private Partnerships running for another five years. These partnerships work with the Food and Drug Administration (FDA) to speed up the development and testing of new medicines and medical devices. The bill increases the funding for these partnerships, boosting their ability to support innovation and improve public health. Specifically, it changes the funding levels to provide more resources for the program through 2027.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Kyrsten Sinema
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.